SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Clinical trials for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CARCINOMA OF HEAD AND NECK trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-phase study tested an experimental drug called QEQ278 in 30 adults with advanced solid tumors, including lung, kidney, esophageal, and head and neck cancers. The main goal was to check the drug's safety and find the right dose. The trial was terminated early, so result…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:31 UTC
-
Head and neck cancer drug combo study ends early
Disease control TerminatedThis study tested a new drug called SAR444245 combined with other cancer treatments for people with head and neck cancer that had spread or come back. The goal was to see if the combination could shrink tumors. The study was stopped early and included 59 adults.
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated May 26, 2026 03:31 UTC
-
Experimental cancer combo trial halted early
Disease control TerminatedThis study tested a new drug called OC-001, either by itself or combined with avelumab (an immunotherapy), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The trial was stopped early, and only 73 people were e…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1, PHASE2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated May 26, 2026 03:30 UTC
-
New drug combo aims to help head and neck cancer patients avoid harsh chemo side effects
Disease control TerminatedThis study tested a new drug called xevinapant combined with standard chemotherapy (carboplatin and paclitaxel) and radiation for people with advanced head and neck cancer who cannot take the usual chemo drug cisplatin. The main goal was to find the safest dose of xevinapant to u…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 26, 2026 03:14 UTC
-
Cancer cocktail falls short: trial halted after only 4 patients
Disease control TerminatedThis study tested whether adding the experimental drug magrolimab to a mix of approved cancer drugs (cetuximab plus either pembrolizumab or docetaxel) could shrink tumors or slow the growth of head and neck cancer that had come back or spread. Only 4 people took part before the t…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Can virtual implants shield jaw bones during cancer radiation?
Knowledge-focused TerminatedThis study tested a new planning method to protect future dental implant sites in head and neck cancer patients receiving radiation therapy. Researchers marked where implants would go before designing the radiation plan, aiming to keep those areas safe without harming tumor cover…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: NA • Sponsor: Institut de cancérologie Strasbourg Europe • Aim: Knowledge-focused
Last updated May 22, 2026 14:03 UTC